Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024

BUY
$0.15 - $0.34 $0 - $1
5 Added 0.12%
4,163 $0
Q3 2023

Nov 13, 2023

BUY
$0.32 - $1.14 $0 - $2
2 Added 0.05%
4,158 $1,000
Q2 2023

Aug 15, 2023

BUY
$0.49 - $0.93 $1 - $3
4 Added 0.1%
4,156 $3,000
Q1 2023

May 12, 2023

BUY
$0.71 - $2.86 $734 - $2,960
1,035 Added 33.21%
4,152 $3,000
Q4 2022

Feb 13, 2023

BUY
$1.72 - $3.13 $1 - $3
1 Added 0.03%
3,117 $5,000
Q3 2022

Nov 14, 2022

BUY
$1.52 - $2.57 $4 - $7
3 Added 0.1%
3,116 $6,000
Q2 2022

Aug 12, 2022

BUY
$2.53 - $4.42 $17 - $30
7 Added 0.23%
3,113 $8,000
Q1 2022

May 16, 2022

BUY
$3.78 - $4.66 $7,749 - $9,553
2,050 Added 194.13%
3,106 $13,000
Q4 2021

Feb 14, 2022

BUY
$4.12 - $6.35 $4,120 - $6,350
1,000 Added 1785.71%
1,056 $5,000
Q2 2021

Aug 16, 2021

SELL
$4.7 - $16.7 $11,016 - $39,144
-2,344 Reduced 97.67%
56 $1,000
Q1 2021

May 13, 2021

SELL
$3.79 - $9.78 $19,025 - $49,095
-5,020 Reduced 67.65%
2,400 $19,000
Q4 2020

Feb 09, 2021

BUY
$3.47 - $4.52 $9,001 - $11,724
2,594 Added 53.75%
7,420 $28,000
Q3 2020

Nov 05, 2020

BUY
$3.55 - $9.99 $5,041 - $14,185
1,420 Added 41.69%
4,826 $17,000
Q2 2020

Aug 13, 2020

BUY
$4.75 - $15.38 $16,178 - $52,384
3,406 New
3,406 $32,000

About Nemaura Medical Inc.


  • Ticker NMRD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 24,102,900
  • Market Cap $723K
  • Description
  • Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. It provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes...
More about NMRD
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.